Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)

Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)

Background. Diffuse large B-cell lymphoma (DLBCL) is a potentially curable biologically heterogeneous lymphatic tumor. Standard R-CHOP therapy shows disappointing results, both immediate and longterm. To improve efficacy without additional toxicity, it is worth considering the possibility of using b...

Full description

Saved in:
Bibliographic Details
Main Authors: M. A. Mingalimov, E. A. Baryakh, A. V. Misyurin, L. A. Kesaeva, A. S. Mkrtchyan, E. N. Misyurina, T. N. Tolstykh, M. S. Orlova, A. A. Akhmadeeva, T. S. Chudnova, D. D. Ivanova, O. L. Kochneva, E. N. Zotina, A. B. Makeshova, S. S. Andreev, K. V. Yatskov, I. V. Samsonova, M. A. Lysenko
Format: Article
Language:Russian
Published: ABV-press 2024-12-01
Series:Онкогематология
Subjects:
diffuse large cell lymphoma
sequencing
genotype
precision immunochemotherapy
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/976
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://oncohematology.abvpress.ru/ongm/article/view/976

Similar Items